MNLO Menlo Therapeutics Inc.

5.46
-0.02  -0%
Previous Close 5.48
Open 5.26
Price To Book 1.53
Market Cap 133,238,365
Shares 24,402,631
Volume 47,761
Short Ratio
Av. Daily Volume 155,809
Stock charts supplied by TradingView

NewsSee all news

  1. Menlo Therapeutics CEO to Participate in Fireside Chat at the Piper Jaffray 31st Annual Healthcare Conference

    REDWOOD CITY, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch),

  2. Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

    Combination establishes a dermatology-focused company with a broad portfolio of an approved product and late-stage dermatology assetsMenlo's serlopitant for pruritus associated with prurigo nodularis ("PN") complements

  3. Menlo Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

    REDWOOD CITY, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch),

  4. Menlo Therapeutics to Present at the HC Wainwright 21st Annual Global Investment Conference

    REDWOOD CITY, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch),

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 planned for 2020.
Serlopitant
Pruritus associated with psoriasis
Phase 3 data due March/April 2020.
Serlopitant
Pruritus associated with prurigo nodularis
Phase 2 data released October 8, 2018. Endpoints not met.
Serlopitant
Refractory chronic cough
Phase 2 data released April 9, 2018. Endpoints not met.
Serlopitant
Pruritus associated with atopic dermatitis
Phase 2 data due January/February 2020.
Serlopitant
Chronic pruritus of unknown origin

Latest News

  1. Menlo Therapeutics CEO to Participate in Fireside Chat at the Piper Jaffray 31st Annual Healthcare Conference

    REDWOOD CITY, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch),

  2. Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

    Combination establishes a dermatology-focused company with a broad portfolio of an approved product and late-stage dermatology assetsMenlo's serlopitant for pruritus associated with prurigo nodularis ("PN") complements

  3. Menlo Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

    REDWOOD CITY, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch),

  4. Menlo Therapeutics to Present at the HC Wainwright 21st Annual Global Investment Conference

    REDWOOD CITY, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch),